Methods for determining drug efficacy using cereblon-associated proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9857359
SERIAL NO

13931642

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CELGENE CORPORATIONROUTE 206 AND PROVINCE LINE ROAD PRINCETON NJ 08543

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chopra, Rajesh Summit, US 66 1262
Corral, Laura La Jolla, US 18 216
Jackson, Pilgrim San Diego, US 8 76
Lopez-Girona, Antonia San Diego, US 57 419
Schafer, Peter H Belle Mead, US 76 837
Wang, Maria Yinglin San Diego, US 5 84

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 2, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 2, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00